A Phase 2/3 interventional study of BHV-7000 and BHV-7000 in Focal Epilepsy, sponsored by Biohaven Therapeutics Ltd.. Active, not recruiting at 104 sites in 12 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by Biohaven Therapeutics Ltd. · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 102 studies in Epilepsies, Partial with a site in United States — 18 open to participants now, 24 under way, 6 of them phase 3. Epilepsies, Partial · United States.
Among the 102 studies in Epilepsies, Partial with a site in United States, this one is the 11th largest by planned enrollment of the 86 interventional ones that give a count, is one of 6 that started in 2024, is one of 3 in phase 2/3, reaches primary completion later than 3 of the 22 other live ones, and was the 88th registered.
243 studies on the registry are indexed under Epilepsies, Partial; 49 are open to participants now.
Browse Epilepsies, Partial studies →18 of the 102 studies in Epilepsies, Partial with a site in United States are open now. Recruiting first, the newest first:
Rapport Therapeutics Inc. · Sites in United States, Australia, Korea, Republic of
Ages 18–75
Rapport Therapeutics Inc. · Sites in United States, Australia, Korea, Republic of and 1 more country
Ages 18–75
Mayo Clinic · Sites in United States
Ages 18–75
Rapport Therapeutics Inc. · Sites in United States
Ages 18–70
University of California, San Francisco · Sites in United States
Ages 21–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 37 Epilepsies, Partial studies recruiting now, 9 (24%) set no upper age limit and 24 (65%) stop at 75 or younger; 17 take children under 18; 3 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
102 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 28 · Phase 3 34 · Phase 4 9
First in 1992; this study’s year is marked. 6 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 390 is above the median of 90 across 187 interventional studies indexed under Epilepsies, Partial.
Median enrollment 100 across the 86 interventional studies, 100 across the 16 observational. Of the 73 that completed or were terminated, 37 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
63 of 102 have an industry lead sponsor. The 10 most frequent:
Biohaven Therapeutics Ltd. is the lead sponsor of 20 studies on the registry; 9 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Biohaven Therapeutics Ltd. has 3 studies filed under Epilepsies, Partial — fewer than ten, so there is no comparison to draw.
10 of the studies in Epilepsies, Partial with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06132893Phase 3Biohaven Therapeutics Ltd.A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy | 2026-12 |
| NCT07505004Phase 3Praxis Precision MedicinesRandomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Focal Seizures | 2027-01 |
| NCT06443463Biohaven Therapeutics Ltd.Long-term Safety and Tolerability of BHV-7000 | 2026-12 |
| NCT05673915Mayo ClinicStudy of Transcranial Direct Current Stimulation to Treat Epilepsy | 2026-12 |
| NCT05794295University of California, DavisSleep Architecture & Cognition in Focal Epilepsy | 2026-12-01 |
Add all 10 to your calendar (.ics) → With an account.
Among the 102 studies in Epilepsies, Partial with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy.
This study has two parts, Part A and Part B. Part A is randomized 1:1:1 25 mg of BHV-7000, 50 mg of BHV-7000 or matching placebo. Part B is randomized 1:1 75mg BHV-7000 or matching placebo. Part B will start after Part A.
Key Inclusion Criteria:
Diagnosis of Focal Onset Epilepsy at least 1 year prior to screening visit defined by 2017 International League Against Epilepsy (ILAE) Classification and based on requirements of Epilepsy Adjudication criteria.
a. Focal seizures i. Focal aware seizures with clinically observable signs and/or symptoms ii. Focal impaired awareness seizures iii. Focal to bilateral tonic-clonic seizures
Key Exclusion Criteria:
Drug: BHV-7000
Drug: BHV-7000
Drug: Placebo
Drug: BHV-7000
Drug: Placebo
BHV-7000 25 mg. Participants will take blinded investigational product (IP) once daily
BHV-7000 50 mg. Participants will take blinded investigational product (IP) once daily
Matching placebo taken once daily
BHV-7000 75 mg. Participants willtake blinded investigational product(IP) once daily
Matching placebo taken once daily
Part B: Change from Baseline in 28-day average seizure frequency
To compare the efficacy of each of 2 doses of BHV-7000 to placebo as an adjunctive therapy for refractory focal onset epilepsy as measured by the change from OP (observational phase) in 28-day average seizure frequency. The primary objective will be measured by comparing the observation phase (8 weeks) to the 12-week double-blind treatment phase.
Time frame: Baseline, Week 8 to Week 20 of Part B
Part A: Number of Participants With Deaths, Serious AEs (SAEs), AEs Leading to Study Drug Discontinuation, and moderate or severe AEs
To assess the safety and tolerability of BHV-7000. This objective will be measured by assessing the number of unique subjects with deaths, SAEs, AEs leading to discontinuation, and moderate and severe AEs.
Time frame: Week 8 to Week 20 of Part A
Part A: Number of Participants With Clinically Significant Laboratory Abnormalities
To assess the safety and tolerability of BHV-7000. This objective will be measured by assessing the number of unique subjects with grade 3 and 4 laboratory abnormalities.
Time frame: Week 8 to Week 20 of Part A
Part B: Percentage of Participants with at at least 50% reduction in seizure frequency per month
To compare the efficacy of 2 dose strengths of BHV-7000 to placebo as adjunctive therapy for refractory focal onset epilepsy as measured by the proportion of subjects that have at least a 50% reduction in seizures per month (28 days). This objective will be measured by comparing the proportion of subjects with at least a 50% reduction in 28-day average seizure frequency over the course of the 12 week double-blind phase to the observation phase.
Time frame: Baseline, Week 8 to Week 20 of Part B
Part B: Change from Baseline in 28-day average seizure frequency during first month of treatment
To compare the efficacy of BHV-7000 to placebo during the first month of treatment. This objective will be measured by the change in log-transformed 28-day adjusted seizure frequency from observation phase over the first month of the double blind phase.
Time frame: Baseline, Week 8 to Week 12 of Part B
Part B: Percentage of Participants with at at least 75% reduction in seizure frequency per month
To compare the efficacy of BHV-7000 to placebo as measured by the proportion of subjects that have at least a 75% reduction in seizures per month (28 days). This objective will be measured by comparing the proportion of subjects with at least a 75% reduction in 28-day average seizure frequency over the course of the double-blind phase compared to the observation phase.
Time frame: Baseline, Week 8 to Week 20 of Part B
Part B: Percentage of Participants with seizure freedom during DB Phase
To compare the efficacy of BHV-7000 to placebo on seizure freedom (100% seizure reduction during the DB phase). This objective will be measured by proportion of subjects that are seizure free during the double-blind phase.
Time frame: Week 8 to Week 20 of Part B
Part B: Change from baseline in 7-day adjusted seizure frequency during first week of treatment
To compare the efficacy of BHV-7000 to placebo during the first week of treatment. This objective will be measured by the change in log-transformed 7-day adjusted seizure frequency from observation phase over the first week of the double-blind phase.
Time frame: Baseline, Week 8 to Week 9 of Part B
Part B: Change from baseline in Patient Global Impression of Change (PGI-C)
To compare the efficacy of BHV-7000 to placebo on the patient global impression of change (PGI-C). This objective will be measured by proportion of subjects at week 12 of double-blind treatment phase with a PGI-C response of "minimally improved", "much improved" or "very much improved". This scale is a 7-point Likert scale with response options of: (1) "very much improved" , (2) "much improved", (3) "minimally improved", (4) "no change", (5) "minimally worse", (6) "much worse", (7) and "very much worse"
Time frame: Baseline, Week 20 of Part B
Part B: Number of Participants With Deaths, Serious AEs (SAEs), AEs Leading to Study Drug Discontinuation, and moderate or severe AEs
To assess the safety and tolerability of BHV-7000. This objective will be measured by assessing the number of unique subjects with deaths, SAEs, AEs leading to discontinuation, and moderate and severe AEs.
Time frame: Week 8 to Week 20 of Part B
Part B: Number of Participants With Clinically Significant Laboratory Abnormalities
To assess the safety and tolerability of BHV-7000. This objective will be measured by assessing the number of unique subjects with grade 3 and 4 laboratory abnormalities.
Time frame: Week 8 to Week 20 of Part B
Showing the first 100 of 104 sites across 12 countries. Choose a country and city above to see the rest.
Started Mar 2024 (actual). Primary completion is estimated for Dec 2026, 33 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Opakalim
Biohaven Therapeutics Ltd.